pharma · Multiple Myeloma · Relapsed/Refractory Multiple Myeloma
Janssen-Cilag International N.V
Janssen-Cilag International N.V.
Janssen-Cilag Farmaceutica Ltda is a pharma organization headquartered in São Paulo, EU. Primary therapeutic focus areas include Multiple Myeloma, Relapsed/Refractory Multiple Myeloma, Inflammatory Conditions, Moderately
São Paulo, EU HQ
13 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- São Paulo, EU
- Employees
- 13
- Programs
- 161
- Drugs
- 159
- Patents
- 0
A Phase 1 for Relapsed/refractory B-cell Non…
Phase 1 · other · Relapsed/refractory B-cell Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
A Phase 1 for Relapsed/refractory B-cell Non… for Relapsed/refractory B-cell Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) is a Phase 1 program (other) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Janssen-Cilag International N.V.
- Phase
- Phase 1
- Modality
- other
- Indication
- Relapsed/refractory B-cell Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
- Status
- active
- Trials
- 1